@article{edan:inserm-02457667,
TITLE = {Natalizumab in secondary progressive multiple sclerosis},
AUTHOR = {Edan, Gilles},
URL = {https://inserm.hal.science/inserm-02457667},
NOTE = {Comment onEffect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. [Lancet Neurol. 2018]},
JOURNAL = {The Lancet Neurology},
PUBLISHER = {Elsevier},
VOLUME = {17},
NUMBER = {5},
PAGES = {384-385},
YEAR = {2018},
MONTH = May, DOI = {10.1016/S1474-4422(18)30108-X},
PDF = {https://inserm.hal.science/inserm-02457667/file/1-s2.0-S147444221830108X-main.pdf},
HAL_ID = {inserm-02457667},
HAL_VERSION = {v1},
}